Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded, placebo-controlled phase 3 trial (vol 399, pg 237, 2021)

被引：0
|
作者：
Halperin, S. A.
Ye, L.
MacKinnon-Cameron, D.
机构：
来源：
LANCET | 2022年 / 399卷 / 10321期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded, placebo-controlled phase 3 trial (vol 399, pg 237, 2021)
引用
收藏
页码：236 / 236
页数：1
相关论文
共 11 条
  • [1] Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded, placebo-controlled phase 3 trial
    Halperin, Scott A.
    Ye, Lingyun
    MacKinnon-Cameron, Donna
    Smith, Bruce
    Cahn, Pedro E.
    Ruiz-Palacios, Guillermo M.
    Ikram, Aamer
    Lanas, Fernando
    Lourdes Guerrero, M.
    Munoz Navarro, Sergio Raul
    Sued, Omar
    Lioznov, Dmitry A.
    Dzutseva, Vitalina
    Parveen, Ghazala
    Zhu, Fengcai
    Leppan, Laura
    Langley, Joanne M.
    Barreto, Luis
    Gou, Jinbo
    Zhu, Tao
    LANCET, 2022, 399 (10321): : 237 - 248
  • [2] Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial
    Zhu, Feng-Cai
    Guan, Xu-Hua
    Li, Yu-Hua
    Huang, Jian-Ying
    Jiang, Tao
    Hou, Li-Hua
    Li, Jing-Xin
    Yang, Bei-Fang
    Wang, Ling
    Wang, Wen-Juan
    Wu, Shi-Po
    Wang, Zhao
    Wu, Xiao-Hong
    Xu, Jun-Jie
    Zhang, Zhe
    Jia, Si-Yue
    Wang, Bu-Sen
    Hu, Yi
    Liu, Jing-Jing
    Zhang, Jun
    Qian, Xiao-Ai
    Li, Qiong
    Pan, Hong-Xing
    Jiang, Hu-Dachuan
    Deng, Peng
    Gou, Jin-Bo
    Wang, Xue-Wen
    Wang, Xing-Huan
    Chen, Wei
    LANCET, 2020, 396 (10249): : 479 - 488
  • [3] Immunogenicity and safety of a recombinant adenovirus type-5 COVID-19 vaccine in adults: Data from a randomised, double-blind, placebo-controlled, single-dose, phase 3 trial in Russia
    Lioznov, Dmitry
    Amosova, Irina A.
    Sheetikov, Savely
    Zornikova, Ksenia
    Serdyuk, Yana
    Efimov, Grigory
    Tsyferov, Mikhail
    Khmelevskii, Mikhail
    Afanasiev, Andrei
    Khomyakova, Nadezhda
    Zubkov, Dmitry
    Tikhonov, Anton
    Zhu, Tao
    Barreto, Luis
    Dzutseva, Vitalina
    PLOS ONE, 2023, 18 (03):
  • [4] Safety and immunogenicity of a novel recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in China: preliminary report of a randomised, double-blind, placebo-controlled, phase 1 trial
    Zhu, Feng-Cai
    Hou, Li-Hua
    Li, Jing-Xin
    Wu, Shi-Po
    Liu, Pei
    Zhang, Gui-Rong
    Hu, Yue-Mei
    Meng, Fan-Yue
    Xu, Jun-Jie
    Tang, Rong
    Zhang, Jin-Long
    Wang, Wen-Juan
    Duan, Lei
    Chu, Kai
    Liang, Qi
    Hu, Jia-Lei
    Luo, Li
    Zhu, Tao
    Wang, Jun-Zhi
    Chen, Wei
    LANCET, 2015, 385 (9984): : 2272 - 2279
  • [5] Safety and immunogenicity of a recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in Sierra Leone: a single-centre, randomised, double-blind, placebo-controlled, phase 2 trial
    Zhu, Feng-Cai
    Wurie, Alie H.
    Hou, Li-Hua
    Liang, Qi
    Li, Yu-Hua
    Russell, James B. W.
    Wu, Shi-Po
    Li, Jing-Xin
    Hu, Yue-Mei
    Guo, Qiang
    Xu, Wen-Bo
    Wurie, Abdul R.
    Wang, Wen-Juan
    Zhang, Zhe
    Yin, Wen-Jiao
    Ghazzawi, Manal
    Zhang, Xu
    Duan, Lei
    Wang, Jun-Zhi
    Chen, Wei
    LANCET, 2017, 389 (10069): : 621 - 628
  • [6] Safety and immunogenicity of SARS-CoV-2 recombinant protein vaccine formulations in healthy adults: interim results of a randomised, placebo-controlled, phase 1-2, dose-ranging study (vol 21, pg 1257, 2021)
    Goepfert, P. A.
    Fu, B.
    Chabanon, A-L
    LANCET INFECTIOUS DISEASES, 2022, 22 (08): : E207 - E207
  • [7] Immunity duration of a recombinant adenovirus type-5 vector-based Ebola vaccine and a homologous prime-boost immunisation in healthy adults in China: final report of a randomised, double-blind, placebo-controlled, phase 1 trial
    Li, Jing-Xin
    Hou, Li-Hua
    Meng, Fan-Yue
    Wu, Shi-Po
    Hu, Yue-Mei
    Liang, Qi
    Chu, Kai
    Zhang, Zhe
    Xu, Jun-Jie
    Tang, Rong
    Wang, Wen-Juan
    Liu, Pei
    Hu, Jia-Lei
    Luo, Li
    Jiang, Rong
    Zhu, Feng-Cai
    Chen, Wei
    LANCET GLOBAL HEALTH, 2017, 5 (03): : E324 - E334
  • [8] Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia (vol 397, pg 671, 2021)
    Logunov, D. Y.
    Dolzhikova, I., V
    Shcheblyakov, D., V
    LANCET, 2021, 397 (10275): : 670 - 670
  • [9] Efficacy and safety of single-dose fosaprepitant in the prevention of chemotherapy-induced nausea and vomiting in patients receiving high-dose cisplatin: a multicentre, randomised, double-blind, placebo-controlled phase 3 trial (vol 24, pg 1067, 2013)
    Saito, H.
    ANNALS OF ONCOLOGY, 2014, 25 (01) : 300 - 300
  • [10] Safety and Immunogenicity of a Recombinant Adenovirus Type-5-Vectored Coronavirus Disease 2019 (COVID-19) Vaccine With a Homologous Prime-Boost Regimen in Healthy Participants Aged ≥6 Years: A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Trial
    Zhu, Fengcai
    Jin, Pengfei
    Zhu, Tao
    Wang, Wenjuan
    Ye, Huayue
    Pan, Hongxing
    Hou, Lihua
    Li, Jingxin
    Wang, Xue
    Wu, Shipo
    Wang, Ying
    Gou, Jinbo
    Huang, Haitao
    Wu, Hongbin
    Wang, Xuewen
    Chen, Wei
    CLINICAL INFECTIOUS DISEASES, 2022, 75 (01) : E783 - E791
12